Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3429612,ED50s,"The induction of cleft palate demonstrated a linear dose-response by probit analysis: The ED50s were 143.6 mg/kg and 512.0 mg/kg for B10A and B10 mice, respectively.",Hydrocortisone-induced embryotoxicity and embryonic drug disposition in H-2 congenic mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429612/),[mg] / [kg],143.6,485,DB01380,Cortisone acetate
,3429612,ED50s,"The induction of cleft palate demonstrated a linear dose-response by probit analysis: The ED50s were 143.6 mg/kg and 512.0 mg/kg for B10A and B10 mice, respectively.",Hydrocortisone-induced embryotoxicity and embryonic drug disposition in H-2 congenic mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429612/),[mg] / [kg],512.0,486,DB01380,Cortisone acetate
,21336389,flow-rate,"Chromatographic separation was carried out on a Nucleosil 100 C(18) analytical column using a mixture of acetonitrile and water (30 : 70, v/v) as a mobile phase at a flow-rate of 1 mL min(-1).","Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),[ml] / [min],1,14882,DB01380,Cortisone acetate
above,21336389,absolute recoveries,The absolute recoveries of glucocorticoids were above 94.6%.,"Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),%,94.6,14883,DB01380,Cortisone acetate
,21336389,limits of detection (LOD),"The limits of detection (LOD) and quantification (LOQ) were 0.5 and 2 ng mL(-1), respectively, for all analytes.","Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),[ng] / [ml],0.5,14884,DB01380,Cortisone acetate
,21336389,quantification (LOQ),"The limits of detection (LOD) and quantification (LOQ) were 0.5 and 2 ng mL(-1), respectively, for all analytes.","Simultaneous determination of urinary cortisol, cortisone and corticosterone in parachutists, depressed patients and healthy controls in view of biomedical and pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21336389/),[ng] / [ml],2,14885,DB01380,Cortisone acetate
,23594227,time at which maximal concentration,"Doses ≥3 mg were rapidly absorbed (time at which maximal concentration was achieved in plasma, 1.1-1.8 h).",Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594227/),h,1.1-1.8,27194,DB01380,Cortisone acetate
,23594227,trough plasma concentration,"In subjects dosed with 6 mg MK-0916 once daily for 14 days, the mean trough plasma concentration was 240 nm and in vivo cortisone-to-cortisol conversion was inhibited by 84%.",Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594227/),nm,240,27195,DB01380,Cortisone acetate
,23594227,IC50,The relationship between plasma MK-0916 and hepatic 11β-hydroxysteroid dehydrogenase type 1 inhibition was well represented by a simple Emax model with an IC50 of 70.4 nm.,Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23594227/),nm,70.4,27196,DB01380,Cortisone acetate
,17266194,Ki,"This compound had a Ki of 22 nM, possessed low in vivo clearance, and showed a 91% inhibition of adipose 11beta-HSD1 enzymatic activity in a mouse ex vivo pharmacodynamic model.","2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17266194/),nM,22,51362,DB01380,Cortisone acetate
,7131291,ratio,This placental conversion of cortisol to cortisone and the further metabolism and conjugation of cortisol by the fetoplacental unit resulted in a fetal to maternal plasma cortisol ratio of 0.2.,Comparison of the transplacental pharmacokinetics of cortisol and triamcinolone acetonide in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7131291/),,0.2,51824,DB01380,Cortisone acetate
,7131291,ratio,"In contrast, the lack of placental or fetoplacental metabolism of TAC resulted in a fetal to maternal plasma TAC ratio of 0.6.",Comparison of the transplacental pharmacokinetics of cortisol and triamcinolone acetonide in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7131291/),,0.6,51825,DB01380,Cortisone acetate
,6691888,Peak cortisol levels,Peak cortisol levels of 1518 +/- 190 nmol 1(-1) (mean +/- s.e. mean) and 739 +/- 74 nmol 1(-1) were found 1.46 +/- 0.25 and 1.79 +/- 0.16 h after oral cortisol and cortisone acetate respectively.,Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),nM,1518,61438,DB01380,Cortisone acetate
,6691888,Peak cortisol levels,Peak cortisol levels of 1518 +/- 190 nmol 1(-1) (mean +/- s.e. mean) and 739 +/- 74 nmol 1(-1) were found 1.46 +/- 0.25 and 1.79 +/- 0.16 h after oral cortisol and cortisone acetate respectively.,Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),nM,739,61439,DB01380,Cortisone acetate
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,26-91,61440,DB01380,Cortisone acetate
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,54,61441,DB01380,Cortisone acetate
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,21-95,61442,DB01380,Cortisone acetate
,6691888,relative bioavailability,"The relative bioavailability of oral cortisol and cortisone acetate varied widely (cortisol 26-91%, mean 54 +/- 6.9%, cortisone acetate 21-95%, mean 44 +/- 6.5%) but despite this wide variation there was, in individual subjects, a highly significant correlation between the bioavailability of the two steroids (r = 0.870, P less than 0.001).",Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6691888/),%,44,61443,DB01380,Cortisone acetate
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0.94,73046,DB01380,Cortisone acetate
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0,73047,DB01380,Cortisone acetate
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],0.92,73048,DB01380,Cortisone acetate
,8583374,Area under the curves (AUC),"Area under the curves (AUC) of prednisolone before and after the treatment decreased from 0.94 to 0.78 mg h L-1 (P < 0.05) in the Sho-saiko-To group, increased from 0.92 to 1.06 mg h L-1 (P < 0.01) in the Saiboku-To group, and did not change in the Sairei-To group.",Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8583374/),[h·mg] / [l],1,73049,DB01380,Cortisone acetate
,15838928,recovery,The recovery of the 21 GCC when spiked into blank plasma at 5 ng/mL was 45-200% with coefficient of variation (CV) from 0.3-18%.,Simultaneous analysis of twenty-one glucocorticoids in equine plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838928/),%,45-200,77986,DB01380,Cortisone acetate
,15838928,limit of detection (LOD),"The limit of detection (LOD) and that of quantification (LOQ) for most of the analytes were 50-100 pg/mL and 1 ng/mL, respectively, whereas that of confirmation (LOC) was 100-300 pg/mL depending on the analyte.",Simultaneous analysis of twenty-one glucocorticoids in equine plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15838928/),[pg] / [ml],50-100,77987,DB01380,Cortisone acetate
,33713946,flow rate,"The separation of both the compounds was achieved on a Vydac Denali C18 column(250 × 4.6 mm, 5 μm) with a mobile phase composed of 5 mM ammonium acetate buffer-acetonitrile-methanol (43:32:25, v/v) at a flow rate of 0.9 mL/min and UV detection at 240 nm.",Rapid and simultaneous determination of dexamethasone and dexamethasone sodium phosphate using HPLC-UV: Application in microneedle-assisted skin permeation and deposition studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33713946/),[ml] / [min],0.9,78072,DB01380,Cortisone acetate
,2393854,clearance,"The serum concentration of tamoxifen and most of its metabolites ([trans-1(4-beta-hydroxy-ethoxyphenyl)-1,2-diphenylbut-1-ene], 4-hydroxytamoxifen, 4-hydroxy-N-desmethyltamoxifen, N-desmethyltamoxifen, and N-desdimethyltamoxifen) were markedly reduced following aminoglutethimide administration, corresponding to an increase in tamoxifen clearance from 189-608 ml/min.",Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2393854/),[ml] / [min],189-608,88412,DB01380,Cortisone acetate
,7324480,morning level,Cortisone showed a mean morning level of 440 nmol/l +/- 165 nmol/l and a half life of 4.8 hours.,"[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),[nM] / [l],440,101953,DB01380,Cortisone acetate
,7324480,half life,Cortisone showed a mean morning level of 440 nmol/l +/- 165 nmol/l and a half life of 4.8 hours.,"[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,4.8,101954,DB01380,Cortisone acetate
,7324480,half life,"The half life of prednisolone was determined after intravenous injection of 25 mg and found to be 2.4 hours and that of fluocortolone, after oral administration of 60 mg, was calculated to be 1.7 hours.","[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,2.4,101955,DB01380,Cortisone acetate
,7324480,half life,"The half life of prednisolone was determined after intravenous injection of 25 mg and found to be 2.4 hours and that of fluocortolone, after oral administration of 60 mg, was calculated to be 1.7 hours.","[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7324480/),h,1.7,101956,DB01380,Cortisone acetate
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],306,127236,DB01380,Cortisone acetate
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],172,127237,DB01380,Cortisone acetate
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],136,127238,DB01380,Cortisone acetate
,1115177,metabolic clearance rates (MCR),"Corresponding values for the metabolic clearance rates (MCR) of cortisol (by the continuous infusion method) were 306 plus or minus 33, 172 plus or minus 18, 136 plus or minus 14, and 258 plus or minus 23 (S. E.) L. per day.",Estrogen and the metabolism of progesterone in vivo. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1115177/),[l] / [d],258,127239,DB01380,Cortisone acetate
,29795974,bioavailability,"The mean (95% CI) bioavailability of oral hydrocortisone calculated from serum cortisol, unbound serum cortisol and salivary cortisone was 1.00 (0.89-1.14); 0.88 (0.75-1.05); and 0.93 (0.83-1.05), respectively.",Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29795974/),,1.00,140496,DB01380,Cortisone acetate
,29795974,bioavailability,"The mean (95% CI) bioavailability of oral hydrocortisone calculated from serum cortisol, unbound serum cortisol and salivary cortisone was 1.00 (0.89-1.14); 0.88 (0.75-1.05); and 0.93 (0.83-1.05), respectively.",Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29795974/),,0.88,140497,DB01380,Cortisone acetate
,29795974,bioavailability,"The mean (95% CI) bioavailability of oral hydrocortisone calculated from serum cortisol, unbound serum cortisol and salivary cortisone was 1.00 (0.89-1.14); 0.88 (0.75-1.05); and 0.93 (0.83-1.05), respectively.",Bioavailability of Oral Hydrocortisone Corrected for Binding Proteins and Measured by LC-MS/MS Using Serum Cortisol and Salivary Cortisone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29795974/),,0.93,140498,DB01380,Cortisone acetate
,10430255,progression free,Median progression free and overall survival were both 8 months.,Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430255/),month,8,155777,DB01380,Cortisone acetate
,15720518,alpha (t(1/2alpha),"The median alpha (t(1/2alpha)), beta (t(1/2beta)), and gamma (t(1/2gamma)) half-lives were 0.33, 2.2, and 10.7 h respectively.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),h,0.33,161056,DB01380,Cortisone acetate
,15720518,beta (t(1/2beta)),"The median alpha (t(1/2alpha)), beta (t(1/2beta)), and gamma (t(1/2gamma)) half-lives were 0.33, 2.2, and 10.7 h respectively.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),h,2.2,161057,DB01380,Cortisone acetate
,15720518,area under the DXM plasma concentration curve (AUC),The area under the DXM plasma concentration curve (AUC) was 113.5 ng.h/mL.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[h·ng] / [ml],113.5,161058,DB01380,Cortisone acetate
,15720518,plasma concentration,The baseline plasma concentration of COR was 3.5 +/- 0.69 ng/mL and declined significantly (P < 0.02) to 2.9 +/- 0.86 ng/mL at 1 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],3.5,161059,DB01380,Cortisone acetate
,15720518,plasma concentration,The baseline plasma concentration of COR was 3.5 +/- 0.69 ng/mL and declined significantly (P < 0.02) to 2.9 +/- 0.86 ng/mL at 1 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),ng,2.9,161060,DB01380,Cortisone acetate
,15720518,plasma concentration,"The nadir in COR plasma concentration was 0.65 +/- 0.12 ng/mL at 28.8 +/- 9.0 h, and the DXM plasma concentration was 0.19 +/- 0.13 ng/mL.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],0.65,161061,DB01380,Cortisone acetate
,15720518,plasma concentration,"The nadir in COR plasma concentration was 0.65 +/- 0.12 ng/mL at 28.8 +/- 9.0 h, and the DXM plasma concentration was 0.19 +/- 0.13 ng/mL.",Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],0.19,161062,DB01380,Cortisone acetate
,15720518,plasma concentration,Baseline plasma concentration of HYD was 58.8 +/- 11.7 ng/mL and declined significantly (P < 0.001) to 41.1 +/- 14.9 ng/mL at 1 h following DXM administration but recovered to baseline at 96 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),[ng] / [ml],58.8,161063,DB01380,Cortisone acetate
,15720518,plasma concentration,Baseline plasma concentration of HYD was 58.8 +/- 11.7 ng/mL and declined significantly (P < 0.001) to 41.1 +/- 14.9 ng/mL at 1 h following DXM administration but recovered to baseline at 96 h.,Pharmacokinetics of dexamethasone with pharmacokinetic/pharmacodynamic model of the effect of dexamethasone on endogenous hydrocortisone and cortisone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15720518/),ng,41.,161064,DB01380,Cortisone acetate
,16579759,transfer half-life (t(1/2t)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,1.7,165762,DB01380,Cortisone acetate
,16579759,elimination half-life (t(1/2e)),"The median transfer half-life (t(1/2t)) of methylprednisolone from the joint to plasma and elimination half-life (t(1/2e)) from plasma were 1.7 and 19.2 hours, respectively.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),h,19.2,165763,DB01380,Cortisone acetate
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],7.26,165764,DB01380,Cortisone acetate
,16579759,Maximum plasma concentration,"Maximum plasma concentration of methylprednisolone was 7.26 +/- 3.3 ng/mL at 8 hours, which decreased to 0.11 +/- 0.08 ng/mL at 144 hours after injection.",Pharmacokinetics of methylprednisolone acetate after intra-articular administration and its effect on endogenous hydrocortisone and cortisone secretion in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16579759/),[ng] / [ml],0.11,165765,DB01380,Cortisone acetate
,33181621,AUC0-24,"In renal Tx recipients (n = 28), our results indicated a relatively high PL exposure [median, range AUC0-24 = 3821 (2232-5382) mcg h/L], paralleled by strong suppression of endogenous CL profile, demonstrated by a low CL evening-to-morning ratio [median, range 11 (3-47)%].",Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181621/),[h·mcg] / [l],3821,174699,DB01380,Cortisone acetate
,33181621,evening-to-morning ratio,"In renal Tx recipients (n = 28), our results indicated a relatively high PL exposure [median, range AUC0-24 = 3821 (2232-5382) mcg h/L], paralleled by strong suppression of endogenous CL profile, demonstrated by a low CL evening-to-morning ratio [median, range 11 (3-47)%].",Prednisolone and Prednisone Pharmacokinetics in Adult Renal Transplant Recipients. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33181621/),%,11,174700,DB01380,Cortisone acetate
,21786805,IC(50),"Structure based design led directly to 1,3-oxazinan-2-one 9a with an IC(50) of 42 nM against 11β-HSD1 in vitro.","Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21786805/),nM,42,177690,DB01380,Cortisone acetate
,21786805,IC(50),Optimization of 9a for improved in vitro enzymatic and cellular potency afforded 25f with IC(50) values of 0.8 nM for the enzyme and 2.5 nM in adipocytes.,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21786805/),nM,0.8,177691,DB01380,Cortisone acetate
,21786805,IC(50),Optimization of 9a for improved in vitro enzymatic and cellular potency afforded 25f with IC(50) values of 0.8 nM for the enzyme and 2.5 nM in adipocytes.,"Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21786805/),nM,2.5,177692,DB01380,Cortisone acetate
,21786805,oral bioavailability,"In addition, 25f has 94% oral bioavailability in rat and >1000× selectivity over 11β-HSD2.","Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21786805/),%,94,177693,DB01380,Cortisone acetate
,11967038,Intradialytic clearances,Intradialytic clearances were between 120 and 300 mL/min and not sufficient to normalize the steroid concentrations.,Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11967038/),[ml] / [min],120 and 300,188743,DB01380,Cortisone acetate
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,391,193001,DB01380,Cortisone acetate
,17921190,EC(50),"An exposure-response relationship was demonstrated, with an estimated EC(50) of 391 nM (total) and 17 nM (free).","Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17921190/),nM,17,193002,DB01380,Cortisone acetate
,27813051,area under the curve (AUC),"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],55.63,200161,DB01380,Cortisone acetate
,27813051,area under the curve (AUC),"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],37.49,200162,DB01380,Cortisone acetate
,27813051,peak cortisol Cmax,"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],32.61,200163,DB01380,Cortisone acetate
,27813051,peak cortisol Cmax,"The median (interquartile range) area under the curve (AUC) for cortisol was not different for patients, compared with controls [55.63 (32.91-151.07) nmol*min*l-1 vs. 37.49 (27.41-52.00) nmol*min*l-1; p=0.098, respectively], whereas the peak cortisol Cmax was higher in patients [32.61 (5.75-146.19) nmol/l vs. 8.96 (6.96-12.23) nmol/l; p=0.013], compared with controls.",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],8.96,200164,DB01380,Cortisone acetate
,27813051,AUC,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],23.65,200165,DB01380,Cortisone acetate
,27813051,AUC,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[min·nM] / [l],227.73,200166,DB01380,Cortisone acetate
,27813051,peak cortisone Cmax,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],11.11,200167,DB01380,Cortisone acetate
,27813051,peak cortisone Cmax,"The AUC for cortisone [23.65 (6.10-54.76) nmol*min*l-1 vs. 227.73 (200.10-280.52) nmol*min*l-1; p≤ 0.001, respectively], and peak cortisone Cmax was lower in patients than in controls [11.11 (2.91-35.85) nmol/l vs. 33.12 (25.97-39.95) nmol/l; p=0.002].",Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27813051/),[nM] / [l],33.12,200168,DB01380,Cortisone acetate
,32593173,bioavailability,The bioavailability of Nasacthin003 was 14.3%.,Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),%,14.3,204915,DB01380,Cortisone acetate
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],105,204916,DB01380,Cortisone acetate
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],10.3,204917,DB01380,Cortisone acetate
,32593173,repeatability coefficient,"The repeatability coefficient at 60 minutes was 105 nmol/L for IV Synacthen and salivary cortisol and cortisone was 10.3 and 21.1 nmol/L, respectively.",Pharmacodynamic studies of nasal tetracosactide with salivary glucocorticoids for a noninvasive Short Synacthen Test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32593173/),[nM] / [l],21.1,204918,DB01380,Cortisone acetate
,21879982,distribution half-life,"Median distribution half-life was 0.50 hours (range, 0.24 to 0.67 hours); elimination half-life was 6.1 hours (range, 5.0 to 6.4 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,0.50,215233,DB01380,Cortisone acetate
,21879982,elimination half-life,"Median distribution half-life was 0.50 hours (range, 0.24 to 0.67 hours); elimination half-life was 6.1 hours (range, 5.0 to 6.4 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,6.1,215234,DB01380,Cortisone acetate
,21879982,Transfer half-life,"Transfer half-life of TA from joint to plasma was 5.2 hours (range, 0.49 to 73 hours); elimination half-life was 23.8 hours (range, 18.9 to 32.2 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,5.2,215235,DB01380,Cortisone acetate
,21879982,elimination half-life,"Transfer half-life of TA from joint to plasma was 5.2 hours (range, 0.49 to 73 hours); elimination half-life was 23.8 hours (range, 18.9 to 32.2 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,23.8,215236,DB01380,Cortisone acetate
,21879982,Maximum plasma concentration,"Maximum plasma concentration following i.a. administration was 2.0 ng/mL (range, 0.94 to 2.5 ng/mL), and was attained at 10 hours (range, 8 to 12 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),[ng] / [ml],2.0,215237,DB01380,Cortisone acetate
,21879982,Maximum plasma concentration,"Maximum plasma concentration following i.m. administration was 0.34 ng/mL (range, 0.20 to 0.48 ng/mL) and was attained at 13.0 hours (range, 12 to 16 hours); concentration was still quantifiable at 360 hours.","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),[ng] / [ml],0.34,215238,DB01380,Cortisone acetate
,18387858,protein binding,"Since the protein binding of prednisolone did not change in the presence of prednisone (114.0 ng/ml), it appeared that prednisone produced from the therapeutic dose of prednisolone did not affect the unbound fraction of prednisolone.","Simultaneous determination of prednisolone, prednisone, cortisol, and cortisone in plasma by GC-MS: estimating unbound prednisolone concentration in patients with nephrotic syndrome during oral prednisolone therapy. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18387858/),[ng] / [ml],114.0,221418,DB01380,Cortisone acetate
,8829484,peak value,A peak value of 196.6 ng ml-1 cortisol-d5 was observed 30 min after cortisol-d5 administration.,Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],196.6,252205,DB01380,Cortisone acetate
,8829484,peak value,"The peak value of cortisone-d5 was 15.5 ng ml-1 40 min after cortisol-d5 administration, and thereafter cortisone-d5 declined in parallel with the slower decline phase of cortisol-d5.",Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],15.5,252206,DB01380,Cortisone acetate
,8829484,plasma concentrations,The plasma concentrations fell as low as 26.9 ng ml-1 for cortisol-d5 and 4.6 ng ml-1 for cortisone-d5 4 h after cortisol-d5 administration.,Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],26.9,252207,DB01380,Cortisone acetate
,8829484,plasma concentrations,The plasma concentrations fell as low as 26.9 ng ml-1 for cortisol-d5 and 4.6 ng ml-1 for cortisone-d5 4 h after cortisol-d5 administration.,Pharmacokinetic studies of cortisol after oral administration of deuterium-labelled cortisol to a normal human subject. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8829484/),[ng] / [ml],4.6,252208,DB01380,Cortisone acetate
,8126129,half-life of the second elimination phase,The mean (+/-SEM) half-life of the second elimination phase was 11.5 +/- 1.2 h after 1000 mg GRA and 38.7 +/- 10.5 h after 1500 mg GRA (P < 0.05).,Kinetics and dynamics of orally administered 18 beta-glycyrrhetinic acid in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126129/),h,11.5,254301,DB01380,Cortisone acetate
,8126129,half-life of the second elimination phase,The mean (+/-SEM) half-life of the second elimination phase was 11.5 +/- 1.2 h after 1000 mg GRA and 38.7 +/- 10.5 h after 1500 mg GRA (P < 0.05).,Kinetics and dynamics of orally administered 18 beta-glycyrrhetinic acid in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126129/),h,38.7,254302,DB01380,Cortisone acetate
